The relaxin receptor as a therapeutic target – perspectives from evolution and drug targeting

Ross A.d. Bathgate*, Martina Kocan, Daniel J. Scott, M. Akhter Hossain, Sara V. Good, Sergey Yegorov, Jan Bogerd, Paul R. Gooley*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


The peptide relaxin was first identified as an important circulating hormone during pregnancy over 90 years ago. Research over many years defined the numerous biological roles that relaxin plays throughout pregnancy in many mammalian species. These important biological actions have led to the testing of relaxin as a therapeutic agent for a number of indications. The discovery of the relaxin receptor, RXFP1, in 2002 facilitated the better understanding of the cellular targets of relaxin, its mechanism of action and enabled the development of relaxin mimetics and screening for small molecule agonists. Additionally, the rapid expansion of the genome databases and bioinformatics tools has significantly advanced our understanding of the evolution of the relaxin/RXFP1 signaling system. It is now clear that the relaxin-RXFP1 signaling axis is far more ancient than previously appreciated with important roles for invertebrate relaxin-like peptides in reproductive and non-reproductive functions. This review summarizes these advances as well as developments in drug targeting of RXFP1. Hence the complex mode of activation of RXFP1 is discussed as is the discovery and development of a peptide mimetic and small molecule agonist. Detailed signaling studies are summarized which highlight the cell specific signaling of a peptide mimetic and biased signaling of a small molecule agonist. These studies highlight the complexities of targeting peptide GPCRs such as RXFP1.
Original languageEnglish
Pages (from-to)114-132
Number of pages19
JournalPharmacology & Therapeutics
Publication statusPublished - 1 Jul 2018


  • Relaxin
  • insulin-like peptides
  • RXFP1
  • LGR
  • GPCR


Dive into the research topics of 'The relaxin receptor as a therapeutic target – perspectives from evolution and drug targeting'. Together they form a unique fingerprint.

Cite this